Clinical Trial Update: Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Dovitinib and Abiraterone Acetate in metastatic castration-resistant prostate cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Dovitinib (dovitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-03-19